---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055612"
form_type: "8-K"
ticker: null
cik: "0001029142"
company_name: "DYNAVAX TECHNOLOGIES CORP"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:29:59.409209+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dynavax Q1 HEPLISAV-B revenue up 10% to $47.8M; reaffirms 2024 guidance; FDA clears IND for shingles vaccine

## Summary
- HEPLISAV-B net product revenue $47.8M (+10% YoY); total revenue $50.8M; GAAP net loss $8.7M ($0.07/share) vs loss $24.3M ($0.19) YoY.
- Reaffirms FY2024 guidance: HEPLISAV-B revenue $265-280M, gross margin ~80%, R&D $60-75M, SG&A $160-180M, cash to increase.
- U.S. FDA cleared IND for Z-1018 shingles vaccine; Phase 1/2 trial expected Q2 2024 with top-line data H2 2025.
- HEPLISAV-B U.S. market share ~41% (up from 37% YoY); sBLA for hemodialysis under review with PDUFA May 13.
- Cash, equivalents, marketable securities $723.5M; plague vaccine contract modification adds $4M from DoD; Phase 2 data Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-055612
- form_type: 8-K
- cik: 0001029142
- company_name: DYNAVAX TECHNOLOGIES CORP
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1029142/000095017024055612/0000950170-24-055612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029142/000095017024055612/dvax-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055612
- JSON: https://secwatch.observer/filing/0000950170-24-055612.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055612.txt

## Key facts
- Earnings Releases
  DYNAVAX TECHNOLOGIES CORP reported the quarter ended March 31, 2024 results: revenue $50.8 million. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $50.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues for the first quarter of 2024 were $50.8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029142/000095017024055612/0000950170-24-055612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.